THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly

Disclosure: D. Ferone: Advisory Board Member; Self; Recordati, Novartis-AAA, Sandoz, Camurus. Grant Recipient; Self; Bristol-Myers Squibb, Novartis-AAA, Ipsen, Camurus. Research Investigator; Self; Camurus. P. Freda: Research Investigator; Self; Camurus. L. Katznelson: Advisory Board Member; Self; R...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferone, Diego, Freda, Pamela, Katznelson, Laurence, Gatto, Federico, Gilis-Januszewska, Aleksandra, Gordon, Murray B, Kadioglu, Pinar, Maffei, Pietro, Seufert, Jochen R, Silverstein, Julie, Spencer-Segal, Joanna L, Harrie, Maria, Svedberg, Agneta, Tiberg, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554032/
http://dx.doi.org/10.1210/jendso/bvad114.1150

Ejemplares similares

Ejemplares similares